Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares of Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) CEO Cameron Turtle sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $95.51, for a total value of $1,432,650.00. Following the completion of the transaction, the chief executive officer owned 567,540 shares of the company’s stock, valued at $54,205,745.40. This trade represents a 2.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cameron Turtle also recently made the following trade(s):

• On Wednesday, July 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $87.69, for a total value of $1,315,350.00.
• On Monday, June 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The stock was sold at an average price of $70.43, for a total value of $1,056,450.00.

Spyre Therapeutics Trading Down 0.6%

SYRE stock opened at $104.35 on Thursday. Spyre Therapeutics, Inc. has a one year low of $14.51 and a one year high of $108.14. The firm has a market capitalization of $9.18 billion, a PE ratio of -53.51 and a beta of 3.03. The firm has a 50-day moving average of $89.91 and a two-hundred day moving average of $64.66.

Spyre Therapeutics (NASDAQ:SYRE) last announced its earnings results on Tuesday, August 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.40. On average, equities research analysts anticipate that Spyre Therapeutics, Inc. will post -2.86 earnings per share for the current year.

Spyre Therapeutics News Roundup

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Spyre reported a second-quarter loss of $0.36 per share, substantially narrower than the analyst consensus estimate of $0.76. The earnings beat suggests better-than-expected cost management and helped improve investor sentiment. SYRE’s Q2 Loss Narrower Than Expected, Pipeline Progresses
• Positive Sentiment: The company highlighted progress across its Phase 2 development pipeline and upcoming clinical data readouts. These catalysts are particularly important for Spyre because the company remains focused on advancing its therapies rather than generating near-term profits. Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Wedbush raised its price target from $100 to $130 and maintained an “Outperform” rating. Guggenheim also increased its target from $115 to $130 and kept a “Buy” rating, signaling that analysts see additional upside from Spyre’s pipeline and upcoming clinical milestones. Analyst price-target updates

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Wedbush lifted their price objective on shares of Spyre Therapeutics from $100.00 to $130.00 and gave the stock an “outperform” rating in a research report on Wednesday. Citigroup increased their target price on Spyre Therapeutics from $64.00 to $97.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Leerink Partners raised their target price on Spyre Therapeutics from $49.00 to $106.00 and gave the stock an “outperform” rating in a research report on Monday, April 13th. Raymond James Financial began coverage on Spyre Therapeutics in a report on Monday, April 13th. They set a “strong-buy” rating and a $80.00 price target on the stock. Finally, Wolfe Research lowered Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.15.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its stake in shares of Spyre Therapeutics by 26.8% in the 2nd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $59,000 after buying an additional 140 shares in the last quarter. Optimize Financial Inc raised its position in Spyre Therapeutics by 1.5% during the fourth quarter. Optimize Financial Inc now owns 25,331 shares of the company’s stock valued at $830,000 after acquiring an additional 364 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its position in Spyre Therapeutics by 0.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 106,664 shares of the company’s stock valued at $1,788,000 after acquiring an additional 522 shares in the last quarter. Summit Securities Group LLC acquired a new stake in Spyre Therapeutics in the first quarter valued at approximately $28,000. Finally, California State Teachers Retirement System lifted its stake in Spyre Therapeutics by 1.8% in the second quarter. California State Teachers Retirement System now owns 33,201 shares of the company’s stock valued at $497,000 after acquiring an additional 603 shares during the last quarter. 80.39% of the stock is owned by hedge funds and other institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.